NV
Nuvectis Pharma, Inc.
NVCT · NASDAQ
$23.99 +4.49% (+$1.03)
1M +25.73%
Market Cap $636.6M
P/E Ratio -
Div. Yield -
ROE 169.47%
Bulios Fair Price
$17.99
25.0% downside
Current Price
$23.99
Undervalued Fair Value Overvalued
According to Bulios Fair Price, NVCT is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
0 /100
Expensive P/B 70.10x
P/FCF N/A
P/FFO N/A
Growth
75 /100
Growing Book val. growth 9.00%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A FCF margin N/A
Op. margin N/A
Gross margin N/A
Quality
0 /100
Poor Asset turnover 0.00x
ROA 124.45%
ROIC 317.86%
Debt
95 /100
Low Current ratio 1.68x
Debt/Equity 0.00x
Net debt/EBITDA N/A
Stability
56 /100
Moderate EPS volatility 20.75%
Profitable years 0
Beta -0.26x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about NVCT
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Ron Bentsur
Employees
16
Headquarters
Fort Lee
Upcoming events
03 NOV
Earnings
Upcoming earnings report